Home/PharmaSGP/Dr. Markus Fischer
DM

Dr. Markus Fischer

Chief Executive Officer

PharmaSGP

PharmaSGP Pipeline

DrugIndicationPhase
PSG-101Parkinson's Disease (Motor Fluctuations)Phase 2
PSG-102Focal Onset Seizures (Epilepsy)Phase 2
PSG-103Rare Genetic Movement DisorderPhase 1/2
PSG-201Neuropathic PainPhase 1
PSG-301Treatment-resistant DepressionPreclinical
PSG-401Pediatric Neurological DisorderPreclinical